2,4-Dichlorphenyl-(p-tolyl)-methanol | 29334-27-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-Dichlorphenyl-(p-tolyl)-methanol
• 英文别名: (2,4-Dichlorophenyl)(4-methylphenyl)methanol；(2,4-dichlorophenyl)-(4-methylphenyl)methanol
• CAS: 29334-27-8
• 化学式: C₁₄H₁₂Cl₂O
• mdl: MFCD11097394
• 分子量: 267.155
• InChiKey: BVSIWNHEBVFGOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,4-Dichlorphenyl-(p-tolyl)-methanol 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 生成 2,4-Dichloro-1-[chloro-(4-methylphenyl)methyl]benzene
  参考文献：
  名称：

  Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach

  摘要：

  The present study describes the identification via privileged structure-based approach of the benzhydrylpiperazine moiety as a potential scaffold to develop novel CB1 receptor modulators. Efficient structural optimization of the initial four hit compounds led to a high quality lead series, represented by compound 6c. Compound 6c is a highly potent and selective CB1 receptor inverse agonist that is able to reduce body weight in diet-induced obese Sprague-Dawley rats. The preparation of privileged structure-based library, the progression from hit to lead, the structure-activity relationships in the lead series and in vitro and in vivo activity of compound 6c are discussed. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.12.018
• 作为产物：
  描述：

  2,4-二氯苯甲醛 、 4-甲苯硼酸 在 [Pd((CN(C₁₀H₆)C₆H₄NCH₃)2)(H₂O)2]⁽²⁺⁾*2O₃SCF₃^(1-)=[Pd((CN(C₁₀H₆)C₆H₄NCH₃)2)(H₂O)2][O₃SCF₃]2 、 potassium hydroxide 作用下， 以 氯仿 为溶剂， 生成 2,4-Dichlorphenyl-(p-tolyl)-methanol 、 2,4-Dichlorphenyl-(p-tolyl)-methanol
  参考文献：
  名称：

  Axially chiral C2-symmetric N-heterocyclic carbene (NHC) palladium complexes-catalyzed asymmetric arylation of aldehydes with arylboronic acids

  摘要：

  Chiral C-2-symmetric N-heterocyclic carbene (NHC) palladium diaquo complexes 5a-c and the chiral C-2-symmetric NHC-palladium complexes 5d and 5e prepared from (R)-BINAM or H-8-(R)-BINAM could be used as the catalysts for the enantioselective arylation of arylaldehydes with arylboronic acids in which NHC-Pd complex 5a was found to be fairly effective in this reaction to give the corresponding adducts in moderate enantioselectivities along with moderate to good yields. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2010.06.041

文献信息

• Axially chiral C2-symmetric N-heterocyclic carbene (NHC) palladium complexes-catalyzed asymmetric arylation of aldehydes with arylboronic acids
  作者：Rui Zhang、Qin Xu、Xiuchun Zhang、Tao Zhang、Min Shi

  DOI：10.1016/j.tetasy.2010.06.041

  日期：2010.8

  Chiral C-2-symmetric N-heterocyclic carbene (NHC) palladium diaquo complexes 5a-c and the chiral C-2-symmetric NHC-palladium complexes 5d and 5e prepared from (R)-BINAM or H-8-(R)-BINAM could be used as the catalysts for the enantioselective arylation of arylaldehydes with arylboronic acids in which NHC-Pd complex 5a was found to be fairly effective in this reaction to give the corresponding adducts in moderate enantioselectivities along with moderate to good yields. (C) 2010 Elsevier Ltd. All rights reserved.
• Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach
  作者：Tao Meng、Jue Wang、Hongli Peng、Guanghua Fang、Min Li、Bing Xiong、Xin Xie、Yongliang Zhang、Xin Wang、Jingkang Shen

  DOI：10.1016/j.ejmech.2009.12.018

  日期：2010.3

  The present study describes the identification via privileged structure-based approach of the benzhydrylpiperazine moiety as a potential scaffold to develop novel CB1 receptor modulators. Efficient structural optimization of the initial four hit compounds led to a high quality lead series, represented by compound 6c. Compound 6c is a highly potent and selective CB1 receptor inverse agonist that is able to reduce body weight in diet-induced obese Sprague-Dawley rats. The preparation of privileged structure-based library, the progression from hit to lead, the structure-activity relationships in the lead series and in vitro and in vivo activity of compound 6c are discussed. (C) 2009 Elsevier Masson SAS. All rights reserved.